Clinical experience with L-asparaginase.
D001215:Asparaginase / Q000009:adverse effects / Q000627:therapeutic use*; D001854:Bone Marrow Cells; D002648:Child; D004342:Drug Hypersensitivity / Q000209:etiology; D004885:Erwinia / Q000201:enzymology*; D004926:Escherichia coli / Q000201:enzymology*; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D007945:Leukemia, Lymphoid / Q000097:blood / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000188:drug therapy*; D007958:Leukocyte Count; D008111:Liver Function Tests; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000188:drug therapy*; D008545:Melanoma / Q000097:blood / Q000188:drug therapy* / Q000532:radiotherapy; D009325:Nausea / Q000139:chemically induced; D012709:Serum Albumin / Q000032:analysis; D013045:Species Specificity; D014839:Vomiting / Q000139:chemically induced
D012709:Serum Albumin; D005340:Fibrinogen; D001215:Asparaginase